跳至主要内容
临床试验/NCT00296790
NCT00296790已完成4 期

Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)

Sanofi1 个研究点 分布在 1 个国家目标入组 372 人开始时间: 2006年2月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Sanofi
入组人数
372
试验地点
1
主要终点
Evaluate safety and hypnotic efficacy of zolpidem tartrate extended release vs. placebo in treatment of insomnia associated with Generalized Anxiety Disorder when used concomitantly with escitalopram

研究概览

简要总结

A comparison of Zolpidem Tartrate Extended-Release (Ambien CR)vs. Placebo in the Treatment of Insomnia Associated with Generalized Anxiety Disorder (GAD) when Used Concomitantly with Escitalopram (Lexapro - antidepressant).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
21 Years 至 64 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Male or female between the ages of 21and 64 years, inclusive;
  • •Women must use a medically acceptable form of contraception during the entire study period, or: be surgically sterilized, post-menopausal, agree to use double-barrier contraception throughout the study period, or must have a negative urine pregnancy test prior to randomization;
  • •Must meet the diagnostic requirements of Generalized Anxiety Disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders;
  • •Score at least 18 on the Hamilton Rating Scale for Anxiety (HAM-A)
  • •Must be either newly diagnosed or show symptoms of relapse during a period of no drug therapy for anxiety.
  • •Subject must experience sleep disturbances at least three nights per week, for at least one month prior to study entry, based on historical data.
  • •Subject must be stabilized on all long-term medication therapy for at least one month prior to study entry.
  • •History of Post-Traumatic Stress Disorder;
  • •Concomitant Major Depressive Disorder or Bipolar Disorder;
  • •Any abnormal pre-study laboratory values that require clinical intervention
  • •Shift work or requirement for a regular change in sleep schedule by at least six hours within the previous month.
  • •Pregnant or breastfeeding
  • •History of drug addiction, alcoholism, or drug abuse
  • •Currently using a benzodiazepine or SSRI or more than 2 days of use within the 28 days preceding randomization.
  • •A positive urine drug screen for compounds that would interfere with the assessment of a hypnotic.
  • •Use of prescription and non-prescription sedative drugs;
  • •Prior failure to respond to escitalopram therapy for anxiety
  • •The presence of any untreated or uncompensated clinically significant renal, endocrine, gastrointestinal, hepatic, respiratory, cardiovascular, other neurologic, hematologic, oncologic, immunologic, cerebrovascular disease or malignancy.
  • •History of sleep apnea
  • •History of myasthenia gravis
  • •Known hypersensitivity and/or allergy to or previous adverse experience with zolpidem or escitalopram or any of their excipients
  • •Subject is currently participating in another clinical trial (or within 28 days of screening).

排除标准

  • 未提供

结局指标

主要结局

Evaluate safety and hypnotic efficacy of zolpidem tartrate extended release vs. placebo in treatment of insomnia associated with Generalized Anxiety Disorder when used concomitantly with escitalopram

次要结局

  • To show that treating insomnia from beginning of SSRI (Selective Serotonin Reuptake Inhibitor) treatment for anxiety results in improvement in quality of life and possibly greater response to anti-anxiety therapy

研究者

发起方
Sanofi
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验